Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Conditions
Interventions
Agalsidase beta
Agalsidase beta
Locations
12
United States
Decatur, Georgia, United States
Cincinnati, Ohio, United States
Seattle, Washington, United States
Buenos Aires, Argentina
Passo Fundo, Rio Grande do Sul, Brazil
Vancouver, British Columbia, Canada
Start Date
September 1, 2008
Primary Completion Date
June 1, 2015
Completion Date
June 1, 2015
Last Updated
June 29, 2016
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06226987
NCT06065852
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions